DÄ internationalArchiveReferences
References

Original article

The Pharmacotherapy of Neuropsychiatric Symptoms of Dementia

Dtsch Arztebl Int 2010; 107(18): 320-7. DOI: 10.3238/arztebl.2010.0320

Majic, T; Pluta, J; Mell, T; Aichberger, M C; Treusch, Y; Gutzmann, H; Heinz, A; Rapp, M A

1. Devanand DP: Behavioral complications and their treatment in Alzheimer’s disease. Geriatrics 1997; 52 Suppl 2: 37–9. MEDLINE
2. Testad I, Aasland AM, Aarsland D: Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry 2007; 22: 916–21. MEDLINE
3. Snowden M, Sato K, Roy-Byrne P: Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003; 51: 1305–17. MEDLINE
4. Gruber-Baldini AL, Boustani M, Sloane PD, Zimmerman S: Behavioral symptoms in residential care/assisted living facilities: prevalence, risk factors, and medication management. J Am Geriatr Soc 2004; 52: 1610–7. MEDLINE
5. Cohen-Mansfield J, Marx MS, Rosenthal AS: A description of agitation in a nursing home. J Gerontol 1989; 44: M77–84. MEDLINE
6. Keene J, Hope T, Fairburn CG, Jacoby R, Gedling K, Ware CJ: Natural history of aggressive behaviour in dementia. Int J Geriatr Psychiatry 1999; 14: 541–8. MEDLINE
7. Weyerer S, Schäufele M, Hendlmeier I: A comparison of special and traditional inpatient care of people with dementia. Gerontol Geriatr 2005; 38: 85–94. MEDLINE
8. Pantel J, Grell A, Diehm A, Schmitt B, Ebsen I (eds.): Optimierung der Psychopharmaka-Therapie im Altenpflegeheim („OPTimAL“). Eine kontrollierte Interventionsstudie. Psychosoziale Interventionen zur Prävention und Therapie der Demenz. Berlin: Logos 2005.
9. Theison AK, Geisthoff UW, Förstl H, Schröder SG: Agitation in the morning: symptom of depression in dementia? Int J Geriatr Psychiatry 2009; 24: 335–40. MEDLINE
10. American Geriatrics Society; American Association for Geriatric Psychiatry: The American Geriatrics Society and American Association for Geriatric Psychiatry recommendations for policies in support of quality mental health care in U.S. nursing homes. J Am Geriatr Soc 2003; 51: 1299–304. MEDLINE
11. Ballard C, Hanney ML, Theodoulou M, et al.: for the DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151–7. MEDLINE
12. National Institute for Health and Clinical Excellence (NICE). NICE guidelines for dementia: supporting people with dementia and their carers in health and social care. http://guidance.nice.org.uk/CG42
13. Deutscher Ärztetag: Entschließungen zum Tagesordnungspunkt II: Situation pflegebedürftiger Menschen in Deutschland am Beispiel Demenz. Dtsch Arztebl 2008; 105(22): A-1200. VOLLTEXT
14. Folstein MF, Folstein SE, McHugh PR: „Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98. MEDLINE
15. World Health Organization (WHO). Tenth revision oft the International Classification of Diseases, chapter V (F): Mental and behavioural disorders. Diagnostic criteria for research. Geneva: WHO 1993.
16. Gutzmann H, Schmidt KH, Richert A, Petermann A: Dementia Mood Assessment Scale (DMAS): Ein Instrument zur quantitativen Erfassung depressiver Veränderungen bei dementen Patienten. Z Gerontopsychol Psychiatr 2008; 21: 273–80.
17. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38: 143–62. MEDLINE
18. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14. MEDLINE
19. Wilcock GK, Ballard CG, Cooper JA, Loft H: Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69: 341–8. MEDLINE
20. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J: Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001; 158: 892–8. MEDLINE
21. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005 19; 294: 1934–43. MEDLINE
22. Heinz A, Knable MB, Coppola R, et al.: Psychomotor slowing, negative symptoms and dopamine receptor availability—an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res 1998; 31: 19–26. MEDLINE
23. Boyle PA, Malloy PF: Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 17: 91–9. MEDLINE
24. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: 210–6. MEDLINE
25. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde: Praxisleitlinien in Psychiatrie und Psychotherapie: S-3 Leitlinie Demenz. www.dgppn.de/de_kurzversion-leitlinien_30.html